Latest News
Shares of energy drink company Celsius (NASDAQ:CELH)
jumped 8.9% in the afternoon session after Truist analysts upgraded the stock's rating from Hold to Buy and raised the price target from $35 to $45. The analysts added, "In our opinion, the market is already looking past the hiccups of the legacy business in 2024 and the brand's slowdown in 1Q25."
Via StockStory · March 31, 2025
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 12.5% in the morning session after Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research (CBER), resigned on Friday, 28 March 2025. Marks noted his departure was related to "misinformation and lies" around immunization and raised concerns about the Trump administration's ability to "swiftly approve critical vaccines."
Via StockStory · March 31, 2025
Gold hits fresh all-time high amid speculation Trump’s April 2 tariffs could target all trade partners.
Via Talk Markets · March 31, 2025
Via The Motley Fool · March 31, 2025
The world economy is hitting resource limits of many kinds. These limits include oil, coal, and other sources of energy, including uranium, used as a fuel for nuclear power generation.
Via Talk Markets · March 31, 2025
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements.
Via Chartmill · March 31, 2025
Via Benzinga · March 31, 2025
Via Benzinga · March 31, 2025
NNOX earnings call for the period ending December 31, 2024.
Via The Motley Fool · March 31, 2025
Via Benzinga · March 31, 2025
Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today.
Via Chartmill · March 31, 2025
The Fed will be dealing with the worst of both worlds. Tariff-induced inflation and tariff-induced decline in national output.
Via Talk Markets · March 31, 2025
Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from Ayrmid Ltd.
Via Benzinga · March 31, 2025
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).
Via StockStory · March 31, 2025
Highlighting the uncertainty that hangs over the US economy, first-quarter GDP nowcasts from two regional Fed banks report sharply different estimates.
Via Talk Markets · March 31, 2025
Award-winning author Sam Ro: "Investing is like dieting: For many people, attempting to cut out junk food entirely just doesn't work."
Via Benzinga · March 31, 2025